Lymph Node Yield and Survival in Stage I Lung Adenocarcinoma Surgery

400 patient records from a retrospective cohort study analyze the prognostic impact of lymph node yield during sublobar resection for stage I lung adenocarcinoma. The dataset includes survival outcomes and inflammatory cytokine levels, with findings validated against The Cancer Genome Atlas (TCGA) data. A Bayesian meta-analysis further assesses the relationship between lymph node yield and recurrence-free survival.

Use Cases

• Analyze the association between lymph node yield (LNY) categories (≥4 vs. <4 nodes) and recurrence-free survival (RFS) hazard ratios in the 400-patient cohort.
• Model changes in inflammatory cytokine (IFC) levels, such as IL-6 and TNF-α, following different extents of lymph node dissection.
• Validate consensus clustering results from TCGA data that identified immune profile subgroups (Cluster 1 and 2) within the local patient cohort.
• Assess the interaction between LNY and adjuvant immunochemotherapy outcomes using reported hazard ratios and confidence intervals.

Strengths

• Contains data from a defined cohort of 400 patients with stage I lung adenocarcinoma.
• Integrates multiple analysis layers: clinical survival data, laboratory cytokine measurements, and external validation from TCGA.
• Findings are supported by a Bayesian meta-analysis to corroborate the primary cohort results.

Limitations

• The dataset is small in file size (50.8 KB), suggesting it contains summary or supplementary results rather than raw patient-level data.
• As a retrospective study, it may be subject to selection bias and unmeasured confounding factors.
• Clinical applicability is specific to stage I lung adenocarcinoma patients undergoing sublobar resection.

Provenance

Source

figshare, authored by Yongzhong Li.

Collection Method

Retrospective cohort analysis of patient records, with prospective collection of blood samples for cytokine detection.

Freshness

Last updated in March 2026.